He said that "all subjects had the required antibody titers after the second vaccination."
At the same time, he noted that "only six people complained of pain at the injection site, in just a couple of days this problem was solved by itself."
"It is planned, in fact, after the registration of the drug, that the first series of the drug for extended clinical trials will be released in November," Imatdinova quotes TASS.
On September 8, Rospotrebnadzor reported that the final group of volunteers participating in trials of a vaccine against coronavirus infection COVID-19 at the Vector Center had been discharged.
Virologist and Doctor of Medical Sciences Anatoly Altstein, in an interview with the NSN, spoke about possible options for the development of the situation with COVID-19.